Comment on ‘Population-adjusted indirect treatment comparison of maintenance PARP inhibitor with or without bevacizumab versus bevacizumab alone in women with newly diagnosed advanced ovarian cancer’. (Ther Adv Med Oncol. 2021 Sep 30;13:17588359211049639)

Detalles Bibliográficos
Autores principales: Nakai, Hidekatsu, Matsumura, Noriomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126630/
https://www.ncbi.nlm.nih.gov/pubmed/37113737
http://dx.doi.org/10.1177/17588359231168509

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126630/
https://www.ncbi.nlm.nih.gov/pubmed/37113737
http://dx.doi.org/10.1177/17588359231168509

Ejemplares similares